Emcure Pharmaceuticals valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
Price multiples — at each FY-end close
34.96×——
7.14×——
3.65×——
89.32×——
Enterprise multiples
3.76×——
18.41×——
23.44×——
Yield
2.9%——
1.1%——
Reference — adjusted share basis
₹1,865.00——
₹53.35₹48.76₹35.94
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EMCURE₹1,865.00

Emcure Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersMANKINDALKEMTORNTPHARMERISGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹35,359 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E——34.96
P/B——7.14
P/Sales——3.65
Price to Free Cash Flow——89.32
Enterprise Multiples
EV/Sales——3.76
EV/EBITDA——18.41
EV/EBIT——23.44
Yield
Earnings Yield %——2.86
FCF Yield %——1.12
Reference — adjusted share basis
Price (FY-end close, adj.)——1,865.00
EPS (adj.)35.9448.7653.35
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.